Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Open-label, Randomized Clinical Study to Evaluate the Efficacy, Pharmacokinetics, Safety and Tolerability of GFH375 Monotherapy and Combination Therapy as First-line Treatment in Patients With Advanced Non-small Cell Lung Cancer Harboring KRAS G12D Mutation.

NCT07554859 is registered in ClinicalTrials.gov with Genfleet Therapeutics (Shanghai) Inc. as lead sponsor.

NCT NCT07554859
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07554859 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Open-label, Randomized Clinical Study to Evaluate the Efficacy, Pharmacokinetics, Safety and Tolerability of GFH375 Monotherapy and Combination Therapy as First-line Treatment in Patients With Advanced Non-small Cell Lung Cancer Harboring KRAS G12D Mutation.
Lead sponsor
Genfleet Therapeutics (Shanghai) Inc.
Phase
Phase 2
Overall status
Not yet recruiting
Start date
May 20, 2026
Completion date
April 30, 2028
Enrollment
90 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

nsclc (advanced non-small cell lung cancer)